Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib

Status: Completed

Phase of Trial: Phase 0

Latest Information Update: 25 Aug 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Lapatinib (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary)
Indications Advanced breast cancer; Early breast cancer; HER2 positive breast cancer
Focus Pharmacodynamics; Pharmacogenomic

03 Sep 2019 Status changed from active, no longer recruiting to completed.
02 May 2018 Planned End Date changed from 1 Mar 2018 to 1 Mar 2019.
06 Jun 2017 Results (n=23) comparing transcriptome and kinome profiles before and after treatment with FDA-approved anti-HER2 drugs and combinations, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com